Vi Chiu
Hematology & Oncology · Los Angeles, CANPI 1992725865
Payments from drug & device makers
Across 37 payments — averaging $15,519 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$341K
- Astrazeneca UK Limited$108K
- Novartis$78K
- Biontech SE$38K
- United Therapeutics Corporation$8K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $814 from 6 others
What the payments were for
- Food & beverage$975100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $340,800 |
| Astrazeneca UK Limited | 6 | $107,884 |
| Novartis | 7 | $78,000 |
| Biontech SE | 7 | $37,641 |
| United Therapeutics Corporation | 3 | $7,916 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,134 |
| AstraZeneca | 5 | $280 |
| Exelixis Inc. | 1 | $174 |
| Intera Oncology, Inc | 1 | $168 |
| Ipsen Biopharmaceuticals, Inc | 1 | $149 |
| EMD Serono, Inc. | 1 | $29 |
| Array Biopharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$174
- Intera 3000 Implantable Pump$168
- ONIVYDE$149
- IMFINZI$135
How this compares
$574,188 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StivargaRegorafenib | 20 | $454,241 |
| Oxycodone Hcl | 21 | $417 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 18 | $379 |
| Ondansetron OdtOndansetron | 14 | $295 |
| Ondansetron Hcl | 14 | $116 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Los Angeles
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
- Antoni RibasLos Angeles$13M
- Gary SchillerLos Angeles$11.9M
- Matthew RettigLos Angeles$8.2M
- Lasika SeneviratneLos Angeles$8.1M
- Gary BuchschacherLos Angeles$7.9M
- Edward GaronLos Angeles$7.9M
- Gottfried KonecnyLos Angeles$7.6M
- Sven de VosLos Angeles$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.